Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Kalorama Reports | Multiple Sclerosis World Market Outlook to 2011

Multiple Sclerosis World Market Outlook to 2011

Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.

The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. Kalorama's study focusing on the following four treatments:

Copaxone

Avonex

Rebif

Betaseron/Betaferon

As part of its continuing coverage, this report provides:

Overview of Multiple Sclerosis and its Progression.

Complete Incidence and Prevalence Statistics For U.S. and Worldwide.

Triggers and Risk Factors of MS.

Review of Multiple Sclerosis Treatments on the Market

Market Size and Forecasts For Treatements to 2011.

Issues and Trendsfacing MS treatment

New Multiple Sclerosis Treatments in the pipleline.

As part of Kalorama's trusted information -gathering process, intensive research into company, trade and medical literature was supplemented by interviews with experts in the multiple sclerosis treatment industry. Interviews make up the source of forecast and market size figures.

The Multiple Sclerosis market is examined for the U.S., European and Japanese markets.

Published: Jun 1, 2007

110 Pages

PDF Format
Table of Contents
Price: $2,995.00 / €2,003.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions